The effect of melatonin on capecitabine-induced hepatic and renal toxicity in rats
Background
Capecitabine (CAPE), an antimetabolite chemotherapy, can induce hepatic and renal toxicity. Melatonin (MEL), a neurohormone, possesses antioxidant, anti-apoptotic and anti-inflammatory effects. This study investigated the impact of MEL on capecitabine-induced hepatic and renal toxicity.
Methods and materials
Twenty-five male Wistar rats were categorized into five groups for the study. The groups included a control group, MEL10 group (rats receiving daily intraperitoneal injections of 5 mg/kg MEL), CAPE 500 group (rats receiving weekly intraperitoneal injections of 500 mg/kg CAPE), CAPE + MEL five group, and CAPE + MEL 10 group. All groups were treated for a duration of 6 weeks. Various hematological, serological, biochemical, and histopathological assessments were conducted to evaluate the objective of the study.
Results
The administration of CAPE led to significant liver and kidney toxicity, as evidenced by elevated levels of malondialdehyde (MDA), myeloperoxidase (MPO), nitric oxide (NO), as well as serological markers including AST, ALT, ALP, BUN, and creatinine. CAPE exposure also resulted in a reduction in total antioxidant capacity (TAC) and glutathione peroxidase (GPx) levels. Histological examination revealed hyperemia in both liver and kidney tissues exposed to CAPE. However, treatment with MEL demonstrated positive effects. MEL administration alleviated oxidative stress, reduced levels of liver enzymes, BUN, and creatinine, and ameliorated histopathological degenerations. MEL also increased GPx and TAC levels. Moreover, MEL treatment aided in restoring the body weight that was lost due to CAPE exposure.
Conclusion
Our findings indicated that the administration of MEL in rats significantly enhanced the hepatic and renal toxicity induced by CAPE.
Top-30
Journals
|
1
|
|
|
Toxicology and Applied Pharmacology
1 publication, 14.29%
|
|
|
International Journal of Immunopathology and Pharmacology
1 publication, 14.29%
|
|
|
Biomolecules
1 publication, 14.29%
|
|
|
Cancer Chemotherapy and Pharmacology
1 publication, 14.29%
|
|
|
Journal of Clinical Investigation
1 publication, 14.29%
|
|
|
Toxicology Mechanisms and Methods
1 publication, 14.29%
|
|
|
1
|
Publishers
|
1
|
|
|
Elsevier
1 publication, 14.29%
|
|
|
SAGE
1 publication, 14.29%
|
|
|
MDPI
1 publication, 14.29%
|
|
|
Springer Nature
1 publication, 14.29%
|
|
|
American Society for Clinical Investigation
1 publication, 14.29%
|
|
|
Taylor & Francis
1 publication, 14.29%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 14.29%
|
|
|
1
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.